Publications (100) MA. ANTONIA SALUD SALVIA publications

2024

  1. Angiosarcoma cardiaco, un caso clínico

    Revista Española de Casos Clínicos en Medicina Interna (RECCMI), Vol. 9, Núm. 1, pp. 26-28

  2. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis

    Critical Reviews in Oncology/Hematology, Vol. 201

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

  2. Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research

    Cancers, Vol. 15, Núm. 17

  3. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  4. MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions

    International journal of molecular sciences, Vol. 24, Núm. 18

  5. PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

    International journal of molecular sciences, Vol. 24, Núm. 13

  6. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505

2022

  1. Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

    Cancers, Vol. 14, Núm. 5

  2. Cell-Free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions

    Annals of the American Thoracic Society

  3. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

  4. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  5. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial

    Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898

  2. Diving into the pleural fluid: Liquid biopsy for metastatic malignant pleural effusions

    Cancers, Vol. 13, Núm. 11

  3. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  4. Microenvironmental reactive oxygen species in colorectal cancer: Involved processes and therapeutic opportunities

    Cancers, Vol. 13, Núm. 20

  5. Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer

    Pleura and Peritoneum, Vol. 6, Núm. 2, pp. 75-81

  6. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

    Breast, Vol. 56, pp. 35-41

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116